argenex SE (NASDAQ:ARGX) Given Average Rating of “Moderate Buy” by Analysts

argenex SE (NASDAQ:ARGX) has been assigned an average rating of “Moderate Buy” from the twenty-four ratings firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation, eighteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $986.7778.

A number of research firms recently commented on ARGX. Piper Sandler increased their price objective on argenex from $820.00 to $930.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Morgan Stanley boosted their price objective on shares of argenex from $1,070.00 to $1,110.00 and gave the company an “overweight” rating in a research report on Thursday, December 4th. Robert W. Baird downgraded shares of argenex from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 18th. TD Cowen lifted their target price on shares of argenex from $800.00 to $1,146.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Finally, Wolfe Research reiterated a “peer perform” rating on shares of argenex in a report on Monday, November 24th.

Institutional Trading of argenex

A number of hedge funds have recently added to or reduced their stakes in ARGX. Oppenheimer & Co. Inc. increased its stake in shares of argenex by 2.8% during the 4th quarter. Oppenheimer & Co. Inc. now owns 442 shares of the company’s stock valued at $372,000 after acquiring an additional 12 shares during the last quarter. Valeo Financial Advisors LLC grew its holdings in argenex by 0.9% in the fourth quarter. Valeo Financial Advisors LLC now owns 1,372 shares of the company’s stock valued at $1,153,000 after purchasing an additional 12 shares during the period. CI Investments Inc. increased its position in argenex by 2.6% during the fourth quarter. CI Investments Inc. now owns 469 shares of the company’s stock worth $394,000 after purchasing an additional 12 shares during the last quarter. Sound View Wealth Advisors Group LLC increased its position in argenex by 3.4% during the third quarter. Sound View Wealth Advisors Group LLC now owns 396 shares of the company’s stock worth $292,000 after purchasing an additional 13 shares during the last quarter. Finally, Allworth Financial LP raised its stake in argenex by 12.7% during the fourth quarter. Allworth Financial LP now owns 115 shares of the company’s stock worth $97,000 after purchasing an additional 13 shares during the period. 60.32% of the stock is owned by institutional investors and hedge funds.

argenex Stock Performance

Shares of NASDAQ:ARGX opened at $844.41 on Friday. The business’s fifty day moving average price is $831.22 and its two-hundred day moving average price is $805.88. The stock has a market cap of $52.25 billion, a PE ratio of 36.26, a price-to-earnings-growth ratio of 0.73 and a beta of 0.37. argenex has a one year low of $510.05 and a one year high of $934.62.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.